
Opinion|Videos|November 19, 2025
Improving Care for mCRC: Overcoming Barriers and Building Confidence in Community Practice
Panelists discuss how addressing barriers and sharing real-world data can increase community confidence in prescribing third-line metastatic colorectal therapies.
Advertisement
Episodes in this series

Panelists highlight barriers in community practice that limit third-line therapy uptake, including lack of familiarity with new agents and limited access to data.
They discuss strategies such as sharing real-world safety and patient-reported outcomes data, educational initiatives, and peer-to-peer engagement to build clinician confidence.
Improving data dissemination and support structures can help ensure more patients receive evidence-based therapies outside academic centers.
Advertisement
Related to this article

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
FDA Approves First Heart Valve to Keep Pace With Children's Growth
3
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5

